Print page      E-mail page

Press Releases = Add Release to Briefcase Year: All Years 2009 2008 2007 2006 2005 2004 2003 2002 All Releases Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference Jun 5, 2009 9.9 KB   SOUTH SAN FRANCISCO, Calif., June 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the 8th Annual Needham L...   Read more Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer May 28, 2009 17.1 KB   SOUTH SAN FRANCISCO, Calif., May 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated clinical data from its randomized, controlled Phase 2 trial of picoplatin in patients with metastatic colorectal cance...   Read more Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer May 28, 2009 16.6 KB   SOUTH SAN FRANCISCO, Calif., May 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its Phase 2 clinical trial of picoplatin in patients with metastatic castration-resistan...   Read more Poniard Pharmaceuticals Files Shelf Registration May 15, 2009 11.1 KB   SOUTH SAN FRANCISCO, Calif., May 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC) that, when declared effective by the...   Read more Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference May 13, 2009 10.0 KB   SOUTH SAN FRANCISCO, Calif., May 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, will provide a corporate overview at the Leerink Swann Oncolo...   Read more Poniard Pharmaceuticals to Present at the 2009 BIO International Convention May 12, 2009 11.1 KB   SOUTH SAN FRANCISCO, Calif., May 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Ronald Martell, president and chief operating officer, will present at the BIO International Convention on Tuesday, May 1...   Read more Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update May 5, 2009 20.6 KB   SOUTH SAN FRANCISCO, Calif., May 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported financial results for the first quarter ended March 31, 2009, and provided a corporate update. "The completion of enrollment of our pivotal Phase 3 ...   Read more Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer May 5, 2009 14.3 KB   SOUTH SAN FRANCISCO, Calif., May 5, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the independent Data Monitoring Committee (DMC), after review of available information regarding the efficacy, safety and quality of trial conduct, recommends that the SPEAR (Study of Picoplati...   Read more Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology May 4, 2009 13.1 KB   SOUTH SAN FRANCISCO, Calif., May 4, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will present new data from two ongoing Phase 2 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions during the 45th Annual Meeting of the American...   Read more Poniard Pharmaceuticals to Host First Quarter 2009 Financial Results Conference Call on May 5 Apr 28, 2009 10.2 KB   SOUTH SAN FRANCISCO, Calif., April 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call on Tuesday, May 5, 2009 to discuss the Company's first quarter 2009 results and provide a corporate update. J...   Read more Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer Apr 21, 2009 13.9 KB   SOUTH SAN FRANCISCO, Calif. and DENVER, April 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 dose-escalation study of picoplatin in patients with metastatic colorectal cancer (CRC)....   Read more Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability Apr 21, 2009 13.1 KB   SOUTH SAN FRANCISCO, Calif. and DENVER, April 21, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced the presentation of final data from a Phase 1 clinical study of an oral formulation of picoplatin in patients with solid tumors. Resul...   Read more Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology Apr 20, 2009 14.7 KB   SOUTH SAN FRANCISCO, Calif., April 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that results of its Phase 2 clinical trial of picoplatin in patients with recurrent small cell lung cancer (SCLC) were published in the April 20,...   Read more Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting Apr 14, 2009 10.7 KB   SOUTH SAN FRANCISCO, Calif., April 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company will present final data from two Phase 1 clinical trials of picoplatin, the Company's lead product candidate, at poster sessions...   Read more Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Mar 25, 2009 13.3 KB   SOUTH SAN FRANCISCO, Calif., March 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it has reached its enrollment target of 400 patients in the SPEAR (Study of Picoplatin Efficacy After Relapse) trial. This global, pivotal P...   Read more Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization Mar 20, 2009 11.0 KB   SOUTH SAN FRANCISCO, Calif., March 20, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will concentrate its cash resources on the clinical and commercial development of its late-stage oncology candidate, picoplatin. As a res...   Read more Poniard Pharmaceuticals to Present at Needham & Company's Cancer Therapeutics: Today & Tomorrow Conference Mar 19, 2009 9.9 KB   SOUTH SAN FRANCISCO, Calif., March 19, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the Needham & Company Cancer Therapeutics: Today & Tomorrow Con...   Read more Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update Mar 16, 2009 20.1 KB   SOUTH SAN FRANCISCO, Calif., March 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported financial results for the fourth quarter and year ended December 31, 2008, and provided a corporate update. "During the fourth quarter of 2008, w...   Read more Poniard Pharmaceuticals Receives Going Concern Qualification Mar 16, 2009 9.7 KB   SOUTH SAN FRANCISCO, Calif., March 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that its audited financial statements for the fiscal year ended December 31, 2008, included in the Company's Annual Report on Form 10-K, filed on...   Read more Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16 Mar 10, 2009 10.4 KB   SOUTH SAN FRANCISCO, Calif., March 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it has rescheduled its earnings call regarding its fourth quarter and year-end 2008 financial results, which was previo...   Read more Showing 1-20 of 220 releases Page: 1 2 3 4 5 6 7 8 9 10 11  See Next 20

Stock Information PARD - (NASDAQ) $6.68   + 0.02 Jul 2, 2009 4:11 PM ET  Shareholder Tools Investor Briefcase Investor Kit News & Event Alerts Download Library Investor FAQs News Feeds Investor site Section only Quotes delayed at least 20 minutes. Information provided by eSignal.